Welcome to IHPME Events Calendar. View full details on all the happenings by month or list by type of event – we offer a wide array of seminar series, IHPME driven and co-hosted events, continuing education and alumni sponsored events.


Loading Events

« All Events

  • This event has passed.

CCHE Seminar Series – Friday November 7th, 10am – 12pm in HS100

November 7, 2014 @ 10:00 am - 12:00 pm EST

| Free

Event Navigation

As part of the Canadian Centre for Health Economics (CCHE) Friday Health Economics Series, we welcome Dolly Han this Friday November 7th, 10am – 12pm in HS100 (Health Sciences Building 155 College Street). Dolly will explore “Real-World Cost-Effectiveness Analysis Of Second-Line Pemetrexed Versus Docetaxel In The Advanced Non-Small-Cell Lung Cancer Population In Ontario”.

Dolly is a MSc graduate student in the Institute of Health Policy, Management and Evaluation at the University of Toronto, specializing in health technology assessment. She is currently a Submissions Analyst at the pan-Canadian Oncology Drug Review (pCODR). She is also a Student Fellow of the Canadian Centre for Health Economics. She received her undergraduate health sciences degree at the University of Waterloo.


Docetaxel is a common standard treatment for advanced non-small-cell lung cancer in Ontario after first-line platinum-based therapy. In Ontario in 2008, pemetrexed was approved for funding in the second-line setting based on evidence of equal efficacy as docetaxel, with an improved toxicity profile at a higher cost. Net benefit regression was used to determine the cost-effectiveness of pemetrexed compared to docetaxel in the Ontario population using data from health administrative databases. Overall survival was not significantly different in those treated with pemetrexed compared to docetaxel; however, those treated with docetaxel had higher chemotherapy-related toxicities requiring inpatient hospitalization. The incremental net benefit for pemetrexed was -$8611-20,279 for WTP values ranging from $0-150,000/QALY, suggesting that pemetrexed was not cost-effective at the listed drug price. This study illustrated the use of health administrative databases to populate cost and effect outcomes for real-world post-market cost-effectiveness analyses through net benefit regression.

Link to schedule of all CCHE talks:

To be added to the CCHE Health Economics seminar series mailing list please send an e-mail to:


November 7, 2014
10:00 am - 12:00 pm EST
Event Categories:


Health Sciences Building, HS100
155 College Street, Room 100
Toronto, Ontario M5T3M6 Canada
+ Google Map